On 22 September 2008, orphan designation (EU/3/08/568) was granted by the European Commission to Innate Pharmaceuticals AB, Sweden, for N'-(5-chloro-2-hydroxy-3-methylbenzylidene)-2,4-dihydroxybenzhydrazide for the treatment of partial deep dermal and full thickness burn wounds.
Innate Pharmaceuticals AB changed name to Creative Antibiotics Sweden AB in November 2010.
- What are partial deep dermal and full thickness burn wounds?
Partial deep dermal and full thickness burns are deep burns to the skin. The wounds caused by partial deep dermal burns have blisters, and a pale white or yellow colour. Full thickness burns involve all of the skin layers, including the layer of fat under the skin. The wounds are painful and the skin appears dry and leathery, and is no longer elastic. These wounds can become infected with bacteria.
Partial deep dermal and full thickness burns can be life-threatening due to infection and the loss of fluids.
- What is the estimated number of patients affected by the condition?
At the time of designation, partial deep dermal and full thickness burn wounds affected approximately 1 in 10,000 people in the European Union (EU)*. This is equivalent to a total of around 50,000 people, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed based on data from the European Union (EU 27), Norway, Iceland and Liechtenstein. This represents a population of 502,282,000 (Eurostat 2008).
- What treatments are available?
Most partial deep dermal and full thickness burns greater than 3 cm in diameter are best treated with surgery soon after the burn to remove the dead tissue and replace it with healthy skin taken from elsewhere on the body. Many antimicrobial agents and disinfectants are also authorised and used in the EU to treat infections in burn wounds.
Satisfactory argumentation has been submitted by the sponsor to justify the assumption that N'-(5-chloro-2-hydroxy-3-methylbenzylidene)-2,4-dihydroxybenzhydrazide might be of potential significant benefit for the treatment of partial deep dermal and full thickness burn wounds because it has a new mechanism of action. This assumption will have to be confirmed at the time of marketing authorisation. This will be necessary to maintain the orphan status.
- How is this medicine expected to work?
This medicinal product is expected to act by blocking the ‘virulence’ of bacteria such as Pseudomonas aeruginosa. Virulence is the ability of bacteria to cause harm and infection. The medicinal product is expected to do this by stopping the bacteria from injecting their enzymes into human cells.
- What is the stage of development of this medicine?
The effects of N'-(5-chloro-2-hydroxy-3-methylbenzylidene)-2,4-dihydroxybenzhydrazide have been evaluated in experimental models.
At the time of submission of the application for orphan designation, no clinical trials in patients with partial deep dermal and full thickness burn wounds had been initiated.
N'-(5-chloro-2-hydroxy-3-methylbenzylidene)-2,4-dihydroxybenzhydrazide was not authorised anywhere worldwide for partial deep dermal and full thickness burn wounds or designated as an orphan medicinal product elsewhere for this condition, at the time of submission.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 9 July 2008 recommending the granting of this designation.
- Opinions on orphan medicinal product designations are based on the following three criteria:
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- and either the rarity of the condition (affecting not more than five in 10,000 people in the Community) or the insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/08/568: Public summary of positive opinion for orphan designation of N'-(5-chloro-2-hydroxy-3-methylbenzylidene)-2,4-dihydroxybenzhydrazide for the treatment of partial deep dermal and full thickness burn wounds||(English only)||2009-04-24||2011-04-06|
|Disease/condition||Treatment of partial deep dermal and full thickness burn wounds|
|Date of decision||22/09/2008|
|Orphan decision number||EU/3/08/568|
Review of designation
Sponsor’s contact details:
Creative Antibiotics Sweden AB
Innate Pharmaceuticals AB
SE-903 47 Umeå
Telephone: + 46 90 13 66 50
Telefax: + 46 90 71 80 95
For contact details of patients’ organisations whose activities are targeted at rare diseases see:
- Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe.
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.